Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin[®] in Ovarian Cancer Patients
Progressing to study Radspherin[®] in the first-line treatment setting for ovarian cancer IND clearance is now obtained for both lead indications for Radspherin[®]Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2 study for Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. This represents the second U.S. FDA IND clearance for Radspherin®, as last